A Multi-center Study a Single IV Infusion of Allogeneic MPCs in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα Inhibitor
Public ClinicalTrials.gov record NCT01851070. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Double-blind, Randomized, Placebo-controlled, Dose-escalation, Multi-center Study a Single Intravenous Infusion of Allogeneic Mesenchymal Precursor Cells (MPCs) in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα Inhibitor
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Study is a double-blind, randomized, placebo controlled, dose escalating study. The primary objective of this study is to evaluate the safety, tolerability and feasibility of a single intravenous infusion of allogeneic mesenchymal precursor cells (MPCs) compared to placebo at 12 weeks post-infusion in the treatment of patients with active rheumatoid arthritis (RA) who have received methotrexate +/- other DMARDs for at least 6 months prior to screening and who have had an incomplete response to at least one TNF-alpha inhibitor.
Study identification
- NCT ID
- NCT01851070
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 48 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 80 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 2013 (Actual)
- Primary completion
- May 2016 (Actual)
- Completion
- Mar 2017 (Actual)
- Last update posted
- Jun 26, 2020
2013 – 2017
United States locations
- U.S. sites
- 20
- U.S. states
- 13
- U.S. cities
- 20
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Pinnacle Research Group | Anniston | Alabama | 36207 | — |
| Arthrocare Arthritis Care and Research PC | Gilbert | Arizona | 85234 | — |
| Triwest Research Associates | El Cajon | California | 92020 | — |
| UCLA | Los Angeles | California | 90025 | — |
| Inland Rheumatology Clinical Trials Incorporated | Upland | California | 91786 | — |
| Ocala Rheumatology Research Center | Ocala | Florida | 34474 | — |
| Arthritis Center | Palm Harbor | Florida | 34684 | — |
| Sarasota Arthritis Research Center | Sarasota | Florida | 34239 | — |
| McIlwain Medical Group | Tampa | Florida | 33614 | — |
| JHU Arthritis Center Baltimore | Baltimore | Maryland | 21224 | — |
| Arthritis Treatment Center | Frederick | Maryland | 21702 | — |
| Reliant Medical Group | Worcester | Massachusetts | 01605 | — |
| Mayo Clinic | Rochester | Minnesota | 55905 | — |
| Office of Ramesh C. Gupta, MD | Fair Lawn | New Jersey | 07410 | — |
| DJL Clinical Research | Charlotte | North Carolina | 28210 | — |
| Health Research of Oklahoma | Oklahoma City | Oklahoma | 73102 | — |
| University of Pittsburgh | Pittsburgh | Pennsylvania | 15261 | — |
| West Tennessee Research Institute | Jackson | Tennessee | 38305 | — |
| Accurate Clinical Research | Houston | Texas | 77034 | — |
| Texas Arthritis Research Center | San Antonio | Texas | 78217 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 3 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01851070, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 26, 2020 · Synced Nov 11, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01851070 live on ClinicalTrials.gov.